On August 7, REMEGEN rose 5.03% in regular trading, trading at HKD 83.65/share, with turnover of HKD 272 million.

On the news front, the company recently disclosed its mid-term earnings forecast, projecting H1 revenue of approximately RMB 58.5 billion, a year-over-year increase of roughly 433%. Net profit attributable to shareholders is expected to reach approximately RMB 47 billion, swinging from a net loss of RMB 4.5 billion in the same period last year. The earnings surge is primarily driven by continued domestic sales growth of core products Telitacicept and Disitamab Vedotin, as well as a substantial increase in technology licensing revenue from the exclusive licensing agreement signed with AbbVie for RC148, granting AbbVie development, manufacturing, and commercialization rights outside Greater China.

Additionally, the newly published National Essential Drug Catalog has provided further policy tailwinds. Research notes indicate that REMEGEN's key products are positioned to benefit from expanded volume opportunities as the catalog drives accelerated adoption at grassroots medical institutions. The broader pharmaceutical sector traded strongly on the day, creating a sector-wide positive linkage effect.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)